Tracers / [111In]DOTA-TRK-950

[111In]DOTA-TRK-950

Also written as [In-111]In-DOTA-TRK-950

Radionuclide: In-111 t½ 4031.6 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: DOTA-conjugated monoclonal antibody (radioimmunoconjugate)
Target / mechanism: Targets CAPRIN-1, a cancer-specific cell surface antigen, via the anti-CAPRIN-1 humanized monoclonal antibody TRK-950 PMID 40473914
Clinical application: Tumor imaging (SPECT/CT) and radioimmunotherapy of CAPRIN-1-expressing solid tumors, evaluated in preclinical proof-of-concept study PMID 40473914
Theranostic pair: <a href="/tracers/lu177-dotatrk950/">lu177-dotatrk950</a>

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	—	≥ 95%	TRK-950-DOTA	40473914 2025 J Cancer Res Clin Oncol Radiolabeling of TRK-950-DOTA with 111In was performed using a method modified slightly based on previously described

Need this precursor?We can point you to suppliers for [111In]DOTA-TRK-950, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40473914. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40473914: 'Radiolabeling of TRK-950-DOTA with 111In'.